题目内容
(请给出正确答案)
[单选题]
CameL研究显示ITT人群中卡瑞利珠单抗联合化疗组的DCR是()
A.87.3%
B.84.6%
C.74.4%
D.70.4%
答案
A、87.3%
如果结果不匹配,请 联系老师 获取答案
A.87.3%
B.84.6%
C.74.4%
D.70.4%
A、87.3%
A.研究纳入了412例患者接受卡瑞利珠单抗治疗
B.PD-L1表达在25%~50%的患者比例最小
C.PD-L1表达在25%~50%的患者样本小,可能导致误差较大
D.对于EGFR阳性且PD-L1≥50%的患者二线接受卡瑞利珠单抗单药治疗获益显著
A.2 (4.8%)
B.23 (54.8%)
C.12 (28.6%)
D.4 (9.5%)
A.59.5%,7.6个月,未达到
B.59.5%,7.6个月,12.1个月
C.59.5%,8.6个月,12.1个月
D.59.5%,7.6个月,13.1个月
A.171ML
B.175ML
C.179ML
D.184ML
A.阿帕替尼的剂量是500mgqd
B.卡瑞利珠单抗的剂量是200mgQ3W
C.卡瑞利珠单抗的激浪是200mgQ2W
D.未发生≥3级的RCCEP
A.1%
B.2.4%
C.4.8%
D.9%